ClinicalTrials.gg
CompletedNCT03625505Updated Sep 14, 2021

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of Venetoclax and Gilteritinib in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
21st of 31
61 · median 97
Started
2018
the only one that year
Phase 1
6 of 31
1 open now
Registered
12th of 31
by date
Lead sponsor
1 of 31
AbbVie

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 21st largest by enrollment, is the only one that started in 2018, is one of 6 in phase 1, and was the 12th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

A dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of venetoclax, in combination with gilteritinib, in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have failed to respond to, and/or have relapsed or progressed after at least 1 prior therapy.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Cancer
  • Acute Myeloid Leukemia (AML)
  • Relapsed or Refractory AML
  • Pharmacokinetics
  • venetoclax
  • gilteritinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Should have an established, confirmed diagnosis of Acute Myeloid Leukemia (AML) by World Health Organization (2016).
  • Should have failed at least 1 (defined as failure to respond to therapy, and/or progression during or after therapy).
  • Should have an (ECOG) performance status of 0, 1, or 2.
  • Should have adequate hematologic, kidney and liver function as described in the protocol.
  • For participants enrolling into the Expansion Cohort only: a documented FMS-like Tyrosine Kinase (FLT3) mutation in bone marrow or peripheral blood, as described in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia.
  • Has a history of other within 2 years prior to study entry, with exceptions as described in the protocol.
  • Has active central nervous system leukemia.
  • Has a history of chronic (NYHA) class IV heart failure.
  • Has a interval of > 450 ms.
  • Has a chronic respiratory disease that requires continuous oxygen use.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Dose Escalation Venetoclax + Gilteritinib

    Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).

    Drug: Venetoclax · Drug: Gilteritinib

  • Experimental
    Dose Expansion Venetoclax + Gilteritinib

    Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.

    Drug: Venetoclax · Drug: Gilteritinib

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose (RPTD) of Co-administered Study Drugs

    The RPTD of co-administered venetoclax and gilteritinib will be determined during the dose escalation phase of the study. RPTD will be determined using available safety and pharmacokinetics data.

    Time frame: Up to approximately 6 months after the last participant is enrolled

  2. Modified Composite Complete Remission (CRc)

    Modified CRc rate is defined as the proportion of participants with documented complete response (CR) + CR with partial blood count recovery (CRp) + CR with incomplete blood count recovery (CRi) plus Morphologic Leukemia-Free State (MLFS) based on guidelines adapted from the International Working Group (IWG) for Acute Myeloid Leukemia (AML).

    Time frame: Up to approximately 6 months after the last participant is enrolled

Secondary outcomes

  1. Pharmacokinetics - Cmax of Venetoclax

    Maximum observed plasma concentration (Cmax) of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  2. Pharmacokinetics - Cmax of Gilteritinib

    Maximum observed plasma concentration (Cmax) of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  3. Pharmacokinetics - Tmax of Venetoclax

    Time to maximum plasma concentration (Tmax) of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  4. Pharmacokinetics - Tmax of Gilteritinib

    Time to maximum plasma concentration (Tmax) of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  5. Pharmacokinetics - AUCt of Venetoclax

    Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt) of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  6. Pharmacokinetics - AUCt of Gilteritinib

    Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt) of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  7. Pharmacokinetics - AUC0-24 Post-dose of Study Drug of Venetoclax

    Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  8. Pharmacokinetics - AUC0-24 Post-dose of Study Drug of Gilteritinib

    Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of study drug.

    Time frame: Approximately 16 days after first dose of study drug

  9. Composite Complete Remission (CRc) Rate

    CRc is defined as the proportion of participants with documented CR + CRp + CRi based on guidelines adapted from the International Working Group (IWG) for Acute Myeloid Leukemia (AML).

    Time frame: Up to approximately 6 months after the last participant is enrolled

  10. Duration of Response (DOR) of Modified Composite Complete Remission (CRc)

    DOR of modified CRc will be defined as time from the first date achieving modified CRc to disease progression (including morphologic relapse) or death from any cause whichever is earlier.

    Time frame: Up to approximately 6 months after the last participant is enrolled

  11. Complete Remission (CR) + with Partial Hematologic Recovery (CRh)

    It is defined as the proportion of participants achieving CR or CRh based on guidelines adapted from the International Working Group (IWG) for Acute Myeloid Leukemia (AML).

    Time frame: Up to approximately 6 months after the last participant is enrolled

  12. Duration of Response (DOR) of Complete Remission (CR) + Complete Remission with Partial Hematologic Recovery (CRh)

    DOR of CR + CRh will be defined as time from the first date achieving CR and/or CRh to disease progression (including morphologic relapse) or death from any cause whichever is earlier.

    Time frame: Up to approximately 6 months after the last participant is enrolled

  13. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose of study drug until 30 days or 5 half-lives after discontinuation of study drug administration will be collected (up to approximately 4 years)

07

Study locations

11 sites
  • David Geffen School of Medicin /ID# 200166
    Los Angeles, California 90095, United States
  • UC San Francisco Medical Center-Parnassus /ID# 200205
    San Francisco, California 94143-2202, United States
  • Sylvester Comprehensive Cancer /ID# 200268
    Miami, Florida 33136-1002, United States
  • Northwestern Memorial Hospital /ID# 200230
    Chicago, Illinois 60611-2927, United States
  • Norton Cancer Institute /ID# 200623
    Louisville, Kentucky 40202-3700, United States
  • Johns Hopkins University /ID# 200349
    Baltimore, Maryland 21287, United States
  • Mayo Clinic - Rochester /ID# 200346
    Rochester, Minnesota 55905-0001, United States
  • Hackensack Univ Med Ctr /ID# 200229
    Hackensack, New Jersey 07601, United States
  • Weill Cornell Medical College /ID# 200109
    New York, New York 10065, United States
  • Hosp of the Univ of Penn /ID# 200348
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center at Texas Medical Center /ID# 206686
    Houston, Texas 77030-4000, United States
08

References and documents

Publications

  • Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. PubMed 35849791 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2021, 34 months.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 34 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2018
First posted
Aug 10, 2018
StartActual
Oct 18, 2018
Primary completionActual
Aug 31, 2021
CompletionActual
Aug 31, 2021
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03625505
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Oct 18, 2018
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Last update
Sep 14, 2021

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion